Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm neoadjuvant nedaplatin study in esophageal squamous cell carcinoma
ChiCTR1900024628Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nedaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Postoperative pathological complete remission rate. Started Jan 2019; status: recruiting.
02
Drugs
nedaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900024628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024628.